Addex Therapeutics (NASDAQ:ADXN) Trading 3.8% Higher – Should You Buy?

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) shot up 3.8% during trading on Thursday . The company traded as high as $6.99 and last traded at $7.0390. 998 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 4,005 shares. The stock had previously closed at $6.78.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Wednesday, April 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Addex Therapeutics Trading Up 1.5%

The stock has a market capitalization of $8.73 million, a price-to-earnings ratio of -1.24 and a beta of 1.51. The stock’s 50 day moving average is $6.61 and its 200 day moving average is $7.44.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.